Monte Rosa Therapeutics, Inc. (GLUE) Stock Price & Analysis
Monte Rosa Therapeutics, Inc. (GLUE) closed at USD 11.11 on Thursday, October 22, 2026, down 0.98% on the day. The US market is currently closed (pre-market); this is not a live price.
The prior close was USD 11.22; the Oct 22, 2026 session ranged USD 11–11.38 on volume of 1,284,510 shares. Market capitalization is $947.83M, with a 52-week range of USD 9.5–25.77 (NMS). Source: Nexqual, retrieved October 23, 2026 at 10:11 UTC.
Also available as compact Markdown for AI agents: nexqual.com/GLUE.md
Key facts (GLUE)
- Last four reported quarters (through Jun 30, 2026): revenue $28.7M, net income -$161M (-560.9% margin), free cash flow -$32.1M (SEC filings).
- Analysts: Buy (mean 1.80 on a 1–5 scale) (10 analysts), mean target USD 26.88 (range 19–37).
- Total return with dividends: 1Y +7.0% vs S&P 500 +14.9%; 5Y -51.3% vs S&P 500 +80.3%.
- Next earnings: 2026-11-05, EPS estimate USD -0.2, revenue estimate $33.9M.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (GLUE)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | — | — | $0K | $75.6M | $124M | $28.7M |
| Operating income | -$72.9M | -$112M | -$143M | -$81.1M | -$54.2M | -$182M |
| Net income | -$74.0M | -$109M | -$135M | -$72.7M | -$38.6M | -$161M |
| EPS (diluted) | -$2.96 | — | — | — | — | — |
| Free cash flow | -$69.1M | -$105M | -$62.8M | $38.0M | -$27.5M | -$32.1M |
| Operating margin | — | — | — | -107.3% | -43.8% | -633.0% |
| Net margin | — | — | — | -96.1% | -31.2% | -560.9% |
| Revenue growth | — | — | — | — | +63.5% | — |
| Cash + short-term investments | $346M | $54.9M | $128M | $224M | $377M | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jun 30, 2026) (GLUE)
P/S 33.0x · P/B 1.9x · FCF yield -3.38% · Earnings yield -17.00% · Dividend yield (paid, TTM) 0.00%
Analysts (GLUE)
Consensus Buy (mean 1.80 on a 1–5 scale), 10 analysts; mean target USD 26.88 (low 19, high 37).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-05 | HC Wainwright & Co. | Reiterated | Buy | $25 |
| 2026-10-01 | HC Wainwright & Co. | Initiated | Buy | $25 |
| 2026-09-09 | Wedbush | Reiterated | Outperform | $27 |
| 2026-08-25 | Guggenheim | Reiterated | Buy | $28 |
| 2026-08-07 | JP Morgan | Target lowered | Overweight | $31 → $27 |
| 2026-08-07 | Guggenheim | Target lowered | Buy | $35 → $28 |
| 2026-08-07 | Wells Fargo | Target lowered | Overweight | $29 → $27 |
| 2026-08-03 | Wedbush | Target lowered | Outperform | $37 → $27 |
| 2026-06-30 | Guggenheim | Target raised | Buy | $30 → $35 |
Total return (dividends reinvested) (GLUE)
| 1Y (from 2025-10-23) | 5Y (from 2021-10-18) | |
|---|---|---|
| Total return | +7.0% | -51.3% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | +7.1% | -13.4% |
| Volatility (annualized) | 79.3% | 93.7% |
| Max drawdown | -61.5% (Jan 2026→Oct 2026) | -89.2% (Nov 2021→Oct 2023) |
GLUE analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $-0.20 | $-0.38 | -47.0% | $33.9M | 9 |
| Next quarter (ends Dec 2026) | $-0.36 | $-0.41 | -12.4% | $21.7M | 9 |
| Current fiscal year (ends Dec 2026) | $-1.42 | $-1.59 | -11.0% | $68.3M | 9 |
| Next fiscal year (ends Dec 2027) | $-1.85 | $-1.81 | +1.8% | $64.6M | 9 |
Key Statistics (as of October 23, 2026 at 10:11 UTC)
| Price | USD 11.11 |
|---|---|
| Change | ▼ 0.98% (down) |
| Previous Close | USD 11.22 |
| Open | USD 11.14 |
| Day Range | USD 11 – 11.38 |
| 52-Week Range | USD 9.5 – 25.77 |
| Volume | 1,284,510 shares |
| Market Cap | $947.83M |
| Exchange | NMS |
Technical Analysis (GLUE)
Nexqual's technical model rates GLUE "NEUTRAL" based on 2 bullish and 3 bearish signals across 127 daily candles, as of October 23, 2026 at 10:11 UTC.
| Overall Signal | NEUTRAL |
|---|---|
| RSI (14) | 46.99 (neutral) |
| vs SMA50 | Below (USD 12.63) |
| MACD | -0.59 (negative) |
Analyst Ratings (GLUE)
Wall Street analysts rate GLUE "Buy" based on 10 analysts, with a mean price target of USD 26.88 (range USD 19–37), per Nexqual as of October 23, 2026 at 10:11 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 10 |
| Mean Target | USD 26.88 |
| High Target | USD 37 |
| Low Target | USD 19 |
| Buy / Hold / Sell | 10 / 0 / 0 |
Earnings (GLUE)
| Next Earnings Date | 2026-11-05 |
|---|---|
| EPS Estimate | USD -0.2 |
| Revenue Estimate | $33.89M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -0.43 vs est -0.37 ▼ miss |
| 2026-03-31 | USD -0.45 vs est -0.38 ▼ miss |
| 2025-12-31 | USD -0.55 vs est -0.34 ▼ miss |
| 2025-09-30 | USD -0.33 vs est -0.35 ▲ beat |
Source: Nexqual, October 23, 2026 at 10:11 UTC.
Financials & Fundamentals (GLUE)
| Total Revenue | $28.73M |
|---|---|
| Revenue Growth (latest quarter, YoY) | -61.30% |
| Gross Margin | +0.00% |
| Operating Margin | -547.84% |
| Profit Margin | +0.00% |
| ROE | -42.66% |
| Debt / Equity | 0.08 |
| Current Ratio | 10.58 |
| Total Cash | $621.10M |
| Total Debt | $37.99M |
| Free Cash Flow (last four quarters to Jun 2026, SEC 10-Q / 10-K) | -$32.08M (-111.7% of revenue) |
Source: Nexqual, October 23, 2026 at 10:11 UTC.
Financial Health Score (GLUE)
Nexqual rates Monte Rosa Therapeutics, Inc.'s overall financial health "Mixed" across five dimensions, as of October 23, 2026 at 10:11 UTC.
| Growth | Strong — Revenue +64% YoY (annual) |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Strong — $621M cash vs $38M debt, net cash position |
| Cash Flow | Weak — FCF negative: -$32M (last 4 quarters to Jun 2026, SEC), burning cash |
| Efficiency | Critical — ROE -43%, ROA -21.6% |
Ownership (GLUE)
| Insider Ownership | +0.56% |
|---|---|
| Institutional Ownership | +116.47% |
| Shares Outstanding | 85.31M |
| Float | 54.48M |
| Short % of Float | +23.44% |
Source: Nexqual, October 23, 2026 at 10:11 UTC.
Leadership (GLUE)
Monte Rosa Therapeutics, Inc. is led by Markus Warmuth, President, CEO & Director, per Nexqual as of October 23, 2026 at 10:11 UTC.
| President, CEO & Director | Markus Warmuth |
|---|---|
| Chief Operating Officer | Jennifer Champoux |
| Chief Technology Officer | Magnus Walter DPHIL |
| Chief Scientific Officer | Sharon Townson |
Major Backers & Investors (GLUE)
Notable institutional backers of Monte Rosa Therapeutics, Inc. include Price (T.Rowe) Associates Inc, NEA Management Company, LLC, T. Rowe Price, according to Nexqual as of October 23, 2026 at 10:11 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Price (T.Rowe) Associates Inc | 10.39% |
| NEA Management Company, LLC | 9.02% |
| T. Rowe Price | 6.37% |
| TCG Crossover Management, LLC | 5.42% |
| Vestal Point Capital, LP | 5.39% |
| BVF Inc. | 5.23% |
| Baker Bros. Advisors, LP | 5.09% |
| Montanova Capital LLC | 4.16% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 8.02% |
| State Street | 4.37% |
Source: Nexqual, October 23, 2026 at 10:11 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| LGND | Ligand Pharmaceuticals Incorpor | USD 307.82 | ▼ 2.21% |
| RYTM | Rhythm Pharmaceuticals, Inc. | USD 90.9 | ▲ 2.57% |
| IOVA | Iovance Biotherapeutics, Inc. | USD 14.14 | ▼ 3.28% |
| PRAX | Praxis Precision Medicines, Inc | USD 258.92 | ▲ 0.96% |
| IONS | Ionis Pharmaceuticals, Inc. | USD 43.91 | ▼ 0.81% |
| ABVX | Abivax SA | USD 90.23 | ▼ 3.49% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 10:11 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt